Doxylamine/pyridoxine (Xonvea®) is indicated for the treatment of nausea and vomiting of pregnancy in women who do not respond to conservative management.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||23/07/2019|
|Rapid review completed||15/08/2019|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that doxylamine/pyridoxine (Xonvea®) not be considered for reimbursement at the submitted price*|
* This recommendation should be considered while also having regard to the criteria
specified in the Health (Pricing and Supply of Medial Goods) Act 2013.